Glucagon Nasal Powder: Treating Hypoglycemia in Individuals With Diabetes Mellitus
Authors:
- Joan S. GrantJGJoan S. Grant
- Michele H. TalleyMTMichele H. Talley
- 31 August 2022
- journal article
- research article
- Published by Elsevier in The Journal for Nurse Practitioners
- Vol. 19 (3) , 104426
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Glucagon: Its evolving role in the management of hypoglycemiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2021
- Glucagon Therapy: A Comparison of Current and Novel TreatmentsDiabetes Spectrum, 2020
- Efficacy and Usability of Intranasal Glucagon for the Management of Hypoglycemia in Patients With Diabetes: A Systematic ReviewClinical Therapeutics, 2020
- Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysisActa Diabetologica, 2020
- Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and AcquaintancesClinical Therapeutics, 2019
- Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 DiabetesDiabetes Care, 2016
- Glucagon Prescription Patterns In Patients With Either Type 1 Or 2 Diabetes With Newly Prescribed InsulinEndocrine Practice, 2016